244 related articles for article (PubMed ID: 24120382)
1. Clinical study evaluating the effect of bevacizumab on the severity of zoledronic acid-related osteonecrosis of the jaw in cancer patients.
Lescaille G; Coudert AE; Baaroun V; Ostertag A; Charpentier E; Javelot MJ; Tolédo R; Goudot P; Azérad J; Berdal A; Spano JP; Ruhin B; Descroix V
Bone; 2014 Jan; 58():103-7. PubMed ID: 24120382
[TBL] [Abstract][Full Text] [Related]
2. Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer treated using zoledronic acid and docetaxel.
Miyazaki H; Nishimatsu H; Kume H; Suzuki M; Fujimura T; Fukuhara H; Enomoto Y; Ishikawa A; Igawa Y; Hirano Y; Homma Y
BJU Int; 2012 Dec; 110(11 Pt B):E520-5. PubMed ID: 22578070
[TBL] [Abstract][Full Text] [Related]
3. Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
Smidt-Hansen T; Folkmar TB; Fode K; Agerbaek M; Donskov F
J Oral Maxillofac Surg; 2013 Sep; 71(9):1532-40. PubMed ID: 23642545
[TBL] [Abstract][Full Text] [Related]
4. Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment?
Pilanci KN; Alco G; Ordu C; Sarsenov D; Celebi F; Erdogan Z; Agacayak F; Ilgun S; Tecimer C; Demir G; Eralp Y; Okkan S; Ozmen V
Medicine (Baltimore); 2015 May; 94(18):e671. PubMed ID: 25950681
[TBL] [Abstract][Full Text] [Related]
5. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
[TBL] [Abstract][Full Text] [Related]
6. Osteonecrosis of the jaw: dental outcomes in metastatic breast cancer patients treated with bisphosphonates with/without bevacizumab.
Ngamphaiboon N; Frustino JL; Kossoff EB; Sullivan MA; O'Connor TL
Clin Breast Cancer; 2011 Aug; 11(4):252-7. PubMed ID: 21729657
[TBL] [Abstract][Full Text] [Related]
7. Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw.
Higuchi T; Soga Y; Muro M; Kajizono M; Kitamura Y; Sendo T; Sasaki A
Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 Jun; 125(6):547-551. PubMed ID: 29574058
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.
Guarneri V; Miles D; Robert N; Diéras V; Glaspy J; Smith I; Thomssen C; Biganzoli L; Taran T; Conte P
Breast Cancer Res Treat; 2010 Jul; 122(1):181-8. PubMed ID: 20361252
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
Vahtsevanos K; Kyrgidis A; Verrou E; Katodritou E; Triaridis S; Andreadis CG; Boukovinas I; Koloutsos GE; Teleioudis Z; Kitikidou K; Paraskevopoulos P; Zervas K; Antoniades K
J Clin Oncol; 2009 Nov; 27(32):5356-62. PubMed ID: 19805682
[TBL] [Abstract][Full Text] [Related]
10. Bisphosphonate-induced osteonecrosis of the jaw (ONJ): Incidence and risk factors in patients with breast cancer and gynecological malignancies.
Fehm T; Beck V; Banys M; Lipp HP; Hairass M; Reinert S; Solomayer EF; Wallwiener D; Krimmel M
Gynecol Oncol; 2009 Mar; 112(3):605-9. PubMed ID: 19136147
[TBL] [Abstract][Full Text] [Related]
11. Rheumatoid Arthritis Exacerbates the Severity of Osteonecrosis of the Jaws (ONJ) in Mice. A Randomized, Prospective, Controlled Animal Study.
de Molon RS; Hsu C; Bezouglaia O; Dry SM; Pirih FQ; Soundia A; Cunha FQ; Cirelli JA; Aghaloo TL; Tetradis S
J Bone Miner Res; 2016 Aug; 31(8):1596-607. PubMed ID: 26950411
[TBL] [Abstract][Full Text] [Related]
12. OPG-Fc but Not Zoledronic Acid Discontinuation Reverses Osteonecrosis of the Jaws (ONJ) in Mice.
de Molon RS; Shimamoto H; Bezouglaia O; Pirih FQ; Dry SM; Kostenuik P; Boyce RW; Dwyer D; Aghaloo TL; Tetradis S
J Bone Miner Res; 2015 Sep; 30(9):1627-40. PubMed ID: 25727550
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapeutic and antiresorptive combination therapy suppressed lymphangiogenesis and induced osteonecrosis of the jaw-like lesions in mice.
Kuroshima S; Yamashita J
Bone; 2013 Sep; 56(1):101-9. PubMed ID: 23727433
[TBL] [Abstract][Full Text] [Related]
14. Osteonecrosis of the jaw in patients with multiple myeloma treated with zoledronic acid.
Cetiner S; Sucak GT; Kahraman SA; Aki SZ; Kocakahyaoglu B; Gultekin SE; Cetiner M; Haznedar R
J Bone Miner Metab; 2009; 27(4):435-43. PubMed ID: 19240969
[TBL] [Abstract][Full Text] [Related]
15. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma.
Corso A; Varettoni M; Zappasodi P; Klersy C; Mangiacavalli S; Pica G; Lazzarino M
Leukemia; 2007 Jul; 21(7):1545-8. PubMed ID: 17410188
[TBL] [Abstract][Full Text] [Related]
16. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.
Dimopoulos MA; Kastritis E; Anagnostopoulos A; Melakopoulos I; Gika D; Moulopoulos LA; Bamia C; Terpos E; Tsionos K; Bamias A
Haematologica; 2006 Jul; 91(7):968-71. PubMed ID: 16757414
[TBL] [Abstract][Full Text] [Related]
17. Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab.
Francini F; Pascucci A; Francini E; Miano ST; Bargagli G; Ruggiero G; Petrioli R
J Am Dent Assoc; 2011 May; 142(5):506-13. PubMed ID: 21531932
[TBL] [Abstract][Full Text] [Related]
18. A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors.
Manfredi M; Mergoni G; Goldoni M; Salvagni S; Merigo E; Meleti M; Vescovi P
Med Oral Patol Oral Cir Bucal; 2017 May; 22(3):e342-e348. PubMed ID: 28390132
[TBL] [Abstract][Full Text] [Related]
19. Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children?
Brown JJ; Ramalingam L; Zacharin MR
Clin Endocrinol (Oxf); 2008 Jun; 68(6):863-7. PubMed ID: 18221397
[TBL] [Abstract][Full Text] [Related]
20. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid.
Cafro AM; Barbarano L; Nosari AM; D'Avanzo G; Nichelatti M; Bibas M; Gaglioti D; Taroni A; Riva F; Morra E; Andriani A
Clin Lymphoma Myeloma; 2008 Apr; 8(2):111-6. PubMed ID: 18501105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
